

*License Number:* 017470NF.  
*Name:* CTX Expres, Inc.  
*Address:* 2450 W. Main St., #202,  
Alhambra, CA 91801.

*Date Revoked:* April 30, 2009.  
*Reason:* Surrendered license  
voluntarily.

*License Number:* 020068NF.  
*Name:* Ice Express LLC. dba Iceexpress.  
*Address:* 120 Nassau Ave., Inwood,  
NY 11096.

*Date Revoked:* May 1, 2009.  
*Reason:* Failed to maintain valid  
bonds.

*License Number:* 020687NF.  
*Name:* MP Transmec USA LLC dba  
TS Lines.

*Address:* 770 Foster Ave.,  
Bensenville, IL 60106.

*Date Revoked:* May 8, 2009.  
*Reason:* Failed to maintain valid  
bonds.

*License Number:* 001593N.  
*Name:* Robertson Forwarding Co., Inc.  
dba RFC Consolidators.

*Address:* 4469 NW 97th Ave., Miami,  
FL 33178.

*Date Revoked:* May 10, 2009.  
*Reason:* Failed to maintain a valid  
bond.

*License Number:* 013172F.  
*Name:* Yung Hoon Kim dba Conex  
International.

*Address:* 20695 South Western Ave.,  
Ste. 136, Torrance, CA 90501.

*Date Revoked:* May 6, 2009.  
*Reason:* Failed to maintain a valid  
bond.

**Sandra L. Kusumoto,**

*Director, Bureau of Certification and  
Licensing.*

[FR Doc. E9-11757 Filed 5-19-09; 8:45 am]

**BILLING CODE 6730-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Nominations to the Advisory Committee on Blood Safety and Availability

**AGENCY:** Department of Health and  
Human Services, Office of the Secretary.

**ACTION:** Notice.

**SUMMARY:** The Office of Public Health  
and Science (OPHS) is seeking  
nominations of qualified individuals to  
be considered for appointment as  
members of the Advisory Committee on  
Blood Safety and Availability (ACBSA).  
ACBSA is a Federal advisory committee  
in the Department of Health and Human  
Services. Management support for the  
activities of this Committee is the  
responsibility of the OPHS.

The qualified individuals will be  
nominated to the Secretary of Health

and Human Services for consideration  
of appointment as members of the  
ACBSA. Members of the Committee,  
including the Chair, are appointed by  
the Secretary. Members are invited to  
serve on the Committee for up to four-  
year terms.

**DATES:** All nominations must be  
received no later than 4 p.m. EDT on  
June 30, 2009, at the address listed  
below.

**ADDRESSES:** All nominations should be  
mailed or delivered to Dr. Jerry  
Holmberg, Executive Secretary,  
Advisory Committee on Blood Safety  
and Availability, Office of Public Health  
and Science, Department of Health and  
Human Services, 1101 Wootton  
Parkway, Suite 250, Rockville, MD  
20852. Telephone: (240) 453-8803.

**FOR FURTHER INFORMATION CONTACT:** Dr.  
Jerry Holmberg, Executive Secretary,  
Advisory Committee on Blood Safety  
and Availability, Office of Public Health  
and Science, Department of Health and  
Human Services, 1101 Wootton  
Parkway, Suite 250, Rockville, MD  
20852. Telephone: (240) 453-8803.

A copy of the Committee charter and  
roster of the current membership can be  
obtained by contacting Dr. Holmberg or  
by accessing the ACBSA Web site at  
<http://www.hhs.gov/bloodsafety>. <http://www.hhs.gov/bloodsafety>.

**SUPPLEMENTARY INFORMATION:** The  
Advisory Committee on Blood Safety  
and Availability advises the Secretary  
and the Assistant Secretary for Health.  
The Committee provides advice on a  
range of policy issues to include: (1)  
Definition of public health parameters  
around safety and availability of the  
blood and blood products, (2) broad  
public health, ethical, and legal issues  
related to transfusion and  
transplantation safety, and (3) the  
implications for safety and availability  
of various economic factors affecting  
product cost and supply.

The ACBSA consists of 20 voting  
members. The Committee is composed  
of 14 public members, including the  
Chair, and six (6) representative  
members. The public members are  
selected from State and local  
organizations, advocacy groups,  
provider organizations, academic  
researchers, ethicists, private  
physicians, scientists, consumer  
advocates, legal organizations, and from  
among communities of persons who are  
frequent recipients of blood or blood  
products. There are six (6) individuals  
designated to serve as official  
representative members of the blood  
and blood products industry or  
professional organizations. These  
representative members shall be from

AABB (formerly the American  
Association of Blood Banks), Plasma  
Protein Therapeutic Association  
(PPTA), one of the two major  
distributors of blood on a rotating basis,  
a trade organization or manufacturer of  
blood, plasma, or other tissue test kits  
or equipment, and a major hospital  
organization that purchases blood and  
blood products.

All ACBSA members are authorized  
to receive the prescribed per diem  
allowance and reimbursement for travel  
expenses that are incurred to attend  
meetings and conduct Committee-  
related business, in accordance with  
Standard Government Travel  
Regulations. Individuals who are  
appointed to serve as public members  
are authorized also to receive a stipend  
for attending Committee meetings and  
to carry out other Committee-related  
business. Individuals who are appointed  
to serve as representative members for a  
particular interest group or industry are  
not authorized to receive a stipend for  
the performance of these duties.

This announcement is to solicit  
nominations of qualified candidates to  
fill positions on the ACBSA that are  
scheduled to be vacated in the public  
member category. The positions are  
scheduled to be vacated on March 1,  
2010.

### Nominations

Persons nominated for appointment  
as members of the ACBSA should be  
among authorities knowledgeable in  
blood banking, transfusion medicine,  
plasma therapies, transfusion and  
transplantation safety, bioethics, and/or  
related disciplines. Nominations should  
be typewritten. The following  
information should be included in the  
package of material submitted for each  
individual being nominated for  
consideration of appointment: (a) The  
name, return address, daytime  
telephone number and affiliation(s) of  
the individual being nominated, the  
basis for the individual's nomination,  
the category for which the individual is  
being nominated, and a statement  
bearing an original signature of the  
nominated individual that, if appointed,  
he or she is willing to serve as a member  
of the Committee; (b) the name, return  
address, and daytime telephone number  
at which the nominator may be  
contacted. Organizational nominators  
must identify a principal contact person  
in addition to the contact; and (c) a copy  
of a current curriculum vitae or resume  
for the nominated individual.

Individuals can nominate themselves  
for consideration of appointment to the  
Committee. All nominations must  
include the required information.

Incomplete nominations will not be processed for consideration. The letter from the nominator and certification of the nominated individual must bear original signatures; reproduced copies of these signatures are not acceptable.

The Department of Health and Human Services is committed to ensuring that women, minority groups, and physically challenged individuals are adequately represented on the Committee. Nominations of qualified candidates from these categories are encouraged. The Department also seeks to have geographic diversity reflected in the composition of the Committee.

The Standards of Ethical Conduct for Employees of the Executive Branch are applicable to individuals who are appointed as public members of Federal advisory committees. Individuals appointed to serve as public members of Federal advisory committees are classified as special Government employees (SGEs). SGEs are Government employees for purposes of the conflict of interest laws. Therefore, individuals appointed to serve as public members of the ACBSA are subject to an ethics review. The ethics review is

conducted to determine if the individual has any interests and/or activities in the private sector that may conflict with performance of their official duties as a member of the Committee. Individuals appointed to serve as public members of the Committee will be required to disclose information regarding financial holdings, consultancies, and research grants and/or contracts.

Dated: May 14, 2009.

**Jerry A. Holmberg,**

*Executive Secretary, Advisory Committee on Blood Safety and Availability.*

[FR Doc. E9-11675 Filed 5-19-09; 8:45 am]

**BILLING CODE 4150-41-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Submission for OMB Review; Comment Request

*Title:* Extension to HS Transportation Requirement.

OMB No.: 0970-0260.

*Description:* The Office of Head Start is proposing to renew authority to collect information regarding the Head Start transportation requirement without changes. The transportation requirement provides the requirement that each child be seated in a child restraint system while the vehicle is in motion, and the requirement that each bus have at least one bus monitor on board at all times. Waivers would be granted when the Head Start or Early Head Start grantee demonstrates that compliance with the requirement(s) for which the waiver is being sought will result in a significant disruption to the Head Start program or the Early Head Start program and that waiving the requirement(s) is in the best interest of the children involved.

*Respondents:* Head Start and Early Head Start program grants recipients.

#### ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Form .....	275	1	1	275

*Estimated Total Annual Burden Hours:* 275.

*Additional Information:* Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov).

*OMB Comment:* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202-395-7245, Attn: Desk Officer for the Administration for Children and Families.

Dated: May 14, 2009.

**Janean Chambers,**

*Reports Clearance Officer.*

[FR Doc. E9-11652 Filed 5-19-09; 8:45 am]

**BILLING CODE 4184-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2008-N-0546]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Data Collection Using MedWatch<sup>Plus</sup> Portal and Rational Questionnaire

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under

the Paperwork Reduction Act of 1995 (the PRA).

**DATES:** Fax written comments on the collection of information by June 19, 2009.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov). All comments should be identified with the OMB control number 0910-NEW and title "Electronic Data Collection Using MedWatch<sup>Plus</sup> Portal and Rational Questionnaire." Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Jonna Capezzuto, Office of Information Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-796-3794.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed